Tracers / [212Pb]Pb-FAPI-46
[212Pb]Pb-FAPI-46
Also written as FAPI-46; [Pb-212]Pb-FAPI-46
- Radionuclide
- Pb-212 t½ 638.4 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- FAP-targeted small molecule inhibitor (FAPI) radioligand
- Target / mechanism
- Targets fibroblast activation protein (FAP) expressed by cancer-associated fibroblasts in tumor stroma PMID 41998481
- Clinical application
- Prostate cancer (targeting cancer-associated fibroblasts in the tumor stroma) PMID 41998481
- Theranostic pair
- <a href="/tracers/ga68-fapi46/">ga68-fapi46</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | >97% | FAPI-46 MedChemExpress | 41998481 2026 EJNMMI Radiopharm Chem FAPI-46 (#HY-137331, MedChemExpress EU, Germany) was dissolved in metal-free water and added to a solution of 10% 5 M sodium acetate (NaAc) in 0.1 M HCl, followed by preheating at 95℃ for 5 min with shaking (450 rpm). |
Need this precursor?We can point you to suppliers for [212Pb]Pb-FAPI-46, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 41998481: 'FAPI-46'.